anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To prevent the nonuniformity and hardening defect of the resin of the molding taken out of a gypsum mold by coating a compsn. contg. a high polymer binder or high polymer film forming agent, light reflective pigment and a solvent as essential components to a gypsum pattern and drying the coating. CONSTITUTION:The high polymer binder or high polymer film forming agent which is used for the photopolymerizable separating agent is soluble in water, includes synthetic products, such as polyvinyl alcohol and natural products, such as gelatin. The high polymer binder or high polymer film forming agent which is soluble in oil includes thermoplastic synthetic high polymers, such as polyvinyl acetate, and natural products, such as colophonium. While pigments of a white system, such as titanium oxide, are mainly exemplified as the light reflective pigment, the difference in the reflective index regulated by the high polymer binder or high polymer film-forming agent and the solvent is preferably &gt;=0.5. Water, acetone, toluene, etc., may be properly used so as to meet the high polymer binder high polymer film-forming agent as the solvent. The film of this separating agent is easily formed by coating this agent to the gypsum mold and drying the coating. The absorption of light by the color of the gypsum mold is eliminated and the effect of retarding the curing of the resin does not arise and, therefore, the post-hardening by a heat treatment is efficiently executed.
The present invention provides dietary compositions for mammalian consumption. In particular, the present invention provides compositions comprising pectin, a component comprising electrolytes, thickening agents, a sweetening agent, and water, and methods for making such compositions. In some embodiments, the dietary compositions are used for preventing and/or treating malabsorption dysfunction and associated disorders (e.g., short bowel syndrome, Crohn&#39;s disease). In some embodiments, the dietary compositions are used for preventing and/or treating colonic disorders (e.g., ulcerative colitis). The dietary compositions further find use in subjects with diarrhea, regardless of cause, subject suffering from gastric dumping syndrome, and obese patients or patients seeking to lose weight, as the composition delays gastric emptying (e.g., creating feeling of early satiety). In some embodiments, the dietary composition is a prebiotic food supplement.
PURPOSE:The titled composition, composed of a mixture of waxes with a specific amount of a nonionic surfactant, having good moldability and easily dispersed into hot water at a relatively low temperature, and capable of easy and safe dewaxing operation. CONSTITUTION:A dental wax composition obtained by mixing at least one of waxes with 2-20wt%, based on the wax, nonionic surfactant. As for the nonionic surfactant, a polyoxyethylene based surfactant prepared by using a higher fatty acid is especially preferred, and usually the one having &gt;=10mol oxyethylene units in one molecule is used. As for the waxes, a mixture of a paraffin based wax with &gt;=1 selected from a beeswax, a microcrystalline wax and a higher fatty acid ester based wax is preferably used. EFFECT:The composition is easily handleable and used as a sprue bar, an impression material etc. in preparation of an artificial tooth, which allows to produce dentures of good quality with good operability without remaining any waxes on the artificial tooth, and does not soil a surrounding apparatus such as drainage pipes when being dewaxed.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a granulated substance as an oral solid preparation that has excellent temporal stability and contains an HMG-CoA reductase inhibitor.  &lt;P&gt;SOLUTION: The granulated substance is obtained by granulating an HMG-CoA reductase inhibitor or a mixture of the inhibitor and a basic amino acid with a gastrosoluble polymer. Preferably the HMG-CoA reductase inhibitor is selected from the group consisting of fluvastatin, atorvastatin, pitavastatin, rosuvastatin and their salts. Preferably the basic amino acid is arginine, lysine or histidine. Preferably the gastrosoluble polymer is a polyvinyl acetal diethyl aminoacetate or an aminoalkyl methacrylate copolymer.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The present disclosure describes a drug and diagnosis contraindication identification platform. The platform may receive a fluid sample from a patient. The fluid sample may be processed to determine one or more substances in the patient&#39;s body. Results may be stored in a laboratory information system. The platform may obtain input data from one or more sources. The platform may also receive, as input, a drug that a healthcare worker is considering prescribing or otherwise recommending to the patient. The platform may cross-reference the proposed drug with the one or more substances in the patient&#39;s body and/or one or more patient diagnoses from the medical record to determine contraindications. The platform may present the compiled information to the health care professional for consideration prior to prescribing or otherwise recommending the drug to the patient. In some embodiments, the information may be compiled and presented in real-time or substantially in real-time.
Systems and methods for online assisted pre-intervention or “prevention” are described. A prevention system may provide the ability to initiate a prevention campaign in order to create a customized support forum for persons who may be afflicted by a harmful addiction. The prevention system can receive a request to initiate a campaign for a recipient from a host and facilitate the invitation of other participants to the campaign. Knowledge-based questionnaires may be dynamically generated for the host and participants, and a profile built for the recipient based on received responses. Customized messages may be generated by the prevention system using expert knowledge-based rules, and delivered to the recipient. The messages may be unique to the recipient based on the recipient&#39;s circumstances and relationship to the host and participants. Support services provided by the prevention system encourage the recipient to agree to accept help and provide action plan recommendations.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new technique for purifying fucoxanthine in high purity and stabilized state even by using sea alga as the raw material.  &lt;P&gt;SOLUTION: Fucoxanthine is produced by extracting the components of the sea alga with ethanol under a light-shielded condition and adsorbing foreign materials with activated carbon. The raw alga of collected state is used as the raw material. The alga is optionally cut to a proper size before the extraction of the components. Concretely, the specified sea algae are those selected from raw Laminaria japonica, raw Undaria pinnatifida, raw Eisenia bicyclis, raw Sargassum fulvellum and raw Hizikia fusifome because these algae contain relatively large amount of fucoxanthine and are available as abundant resources. The ethanol used as the extraction solvent has a concentration of 80-100%.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The invention provides human protein complexes with endonuclease activity. In particular, the invention provides human protein complexes with tRNA splicing endonuclease activity and/or 3&#39; end pre-mRNA endonuclease activity. The invention also provides a splice variant of human Sen2, namely human Sen2deltaEx8, and human protein complexes comprising human Sen2deltaEx8. The human Sen2deltaEx8 complexes have pre-tRNA cleavage activity and/or 3&#39; end pre-mRNA endonuclease activity. The invention also provides human protein complexes with pre-ribosomal RNA cleavage activity. The invention also provides antibodies that immunospecifically bind to a complex described herein or a component thereof, and methods of diagnosing, preventing, treating, managing or ameliorating a disorder utilizing such antibodies. The present invention also provides methods utilizing the complexes described herein, inter alia, in screening, diagnosis, and therapy. The invention further provides methods of preparing and purifying the complexes. The present invention further provides methods of identifying a compound that modulates the expression of a component of a complex described herein, the formation of a complex described herein or the activity of a complex described herein, and methods of preventing, treating, managing or ameliorating a disorder, such as a proliferative disorder, or a symptom thereof utilizing a compound identified in accordance with the methods.
PURPOSE:To obtain the titled fraction usable as an antibody in immunochemical assay, by treating an immunoglobulin prepared from rodents at a specific pH. CONSTITUTION:An immunoglobulin obtained from rodents is treated with pepsine at 2-4pH to give an immunoglobulin F(ab&#39;)2. The amount of the immunoglobulin in carrying out the above-mentioned treatment is 0.1-3wt./ vol.%, preferably 0.3-1wt./vol.%. If the pH in the treatment with the pepsine is adjusted to a more acidic side, the F(ab&#39;)2 can be efficiently obtained. Examples of the pepsine include pepsine prepared by freeze-drying crystalline pepsine obtained from porcine gastric mucus, etc. The concentration of the pepsine is 1/40-2 times based on the amount of the immunoglobulin. The above- mentioned treatment is preferably carried out in a buffer solution, e.g. 0.1M acetic acid buffer solution, etc.
PURPOSE:The titled drug containing a prostaglandin I2 analog compound. CONSTITUTION:A drug containing a compound expressed by formula I (R&lt;1&gt; is H, 1-12C alkyl, 4-7C cycloalkyl, etc.; A is pentyl, cyclopentyl, etc.) or a nontoxic salt of the acid or a cyclodextrin clathrate compound thereof as an active constituent, and having ameliorant action on circulation and antiulcer action. The agent has powerful inhibitory action on blood platelet agglutination, hypotensive action, vasodilator action and antiulcer action, and low toxicity. The agent can be orally or parenterally administered, and the dose thereof is 0.1- 100mg/time, preferably 1mug-1mg/time, and preferably administered one - several times a day. The compound expressed by formula I is obtained by reducing a compound expressed by formula II (R&lt;1&gt;&#39; is 1-2C alkyl, 4-7C cycloalkyl, etc.; R&lt;2&gt; is a protecting group of OH), removing the protecting group from the reduction product and hydrolyzing the resultant product, etc.
The invention discloses application of microRNA-181s (miR-181s for short) in preparing a drug for treating acute enteritis. Specially, the effect of miR-181d is obvious. A fact that the small ribonucleic acid drug of miR-181d, which is modified with cholesterol, is concentratedly distributed in a small intestine is discovered through intravenous administration. The mechanism of action lies in that the small ribonucleic acid drug combines with complementary sequences in the TNF[alpha]3&#39;-UTR area of a tumor necrosis factor to promote the degradation of TNF-[alpha]mRNA, so as to inhibit an acute enteritis reaction induced by TNBS. The small nucleic acid drug is obvious in effect, can be well concentrated in small intestine tissue, and enters cells to take effect. The small ribonucleic acid drug can also act on 3&#39;-UTR of various inflammatory factors containing miR181d binding sequences to inhibit the expression of the inflammatory factors. Therefore, the small nucleic acid drug has high application value and good prospect for treating inflammatory bowel diseases.
The present invention provides systems and methods for monitoring in real time the physiological status of one or more subjects, especially subject engaged in potentially hazardous or dangerous activities. Systems include wearable items with one or more physiological sensors and a local data unit (LDU) operatively coupled to the sensors. The LDUs digitize and filter sensor data, extract physiological parameters, determine abnormal or not acceptable physiological conditions, and communicate to external monitoring facilities.  The external facilities display status and data concerning monitored subjects.  In preferred embodiments, communication between the LDUs and the external monitoring facilities dynamically adjusts to the condition of the subjects and to system changes such as subjects and external facilities entering and leaving and/or moving from place to place. The invention also provides program products for performing this invention&#39;s methods.
Compounds of formula (I)   &lt;IMAGE&gt; (I)  inhibit both the cyclo-oxygenase and lipoxygenase pathways of arachidonic acid oxygenation and are useful in medicine as, e.g., anti-inflammatory and anti-asthmatic agents. The compounds may be administered as the raw chemical or in association with a carrier as a pharmaceutical formulation. The compounds may be prepared by methods analogous to those known in the art, e.g. by the method of Duffin and Kendall in J. Chem. Soc. (1954), 408-415, or by other methods.
PURPOSE:To obtain a drug for administration through body cavity, effective in promoting the absorption of 2&#39;,4&#39;-difluoro-4-hydroxy-3-biphenylcarboxylic acid (an anti-inflammatory analgesic antipyretic agent) through mucosa and improving bioavailability of the compound, by compounding a hydrogenated phospholipid to an oily substrate. CONSTITUTION:The objective agent for administration through body cavity can be produced by dispersing (A) 5-25pts.wt., preferably 15-25pts.wt. of the above compound of formula (general name: diflunisal) in a mixture of (B) 100pts.wt. of an oily substrate and (C) 0.1-10pts.wt., preferably 1-8pts.wt. of a hydrogenated phospholipid. The bioavailability of diflunisal through the mucosa of rectum, cavity, oral cavity of nose, etc., can be improved and the side effects appearing in the conventional oral administration can be avoided. The agent can be easily prepared, has high compatibility to the mucosa of living body and exhibits excellent absorbability of diflunisal.
The present disclosure belongs to the field of health care products, disclosing a powder made from synanthrin, Ganodermae, Coicis Semen, Poria, Atractylodis Macrocephalae Rhizoma, Cuscutae Chinensis Semen, Polygonati Rhizoma, Ophiopogonis Radix, Glycyrrhizae Radix et Rhizoma, Lycii Fructus, Schisandrae Chinensis Fructus and stevioside. The raw materials of the powder are all from natural Chinese herbal medicine without addition of excipient. It is clean and has natural components, in line with people&#39;s pursuit of natural and health foods. In addition, dosage required for the powder is small; it is easy to be taken and can be dissolved in water; it is soluble in cold water and can be absorbed quickly. The method for preparing the powder in the present disclosure is simple and suitable for large-scale production. Also, it is easy to be carried. The powder obtained has a good stability, long storage time, good taste. It melts in mouth and is soluble in cold water. Experiments show that the powder of the present disclosure can significantly enhance immunity, therefore can be used to prepare the health care foods having function on improving immunity.
Improved compositions comprising a mixture of particulate materials with water-based liquids containing water-soluble polymers and surfactants are pr ovided. Examples of particulate powders include mixtures of calcium silicate , calcium aluminate, calcium sulfate, and hydroxyapatite. Examples of water- soluble polymers include polyvinyl alcohols, polyvinyl pyrrolidone, partiall y hydrolyzed polyvinyl acetates, polyacrylic acid, and polymethacrylic acid. Surfactants such as sodium dodecyl sulfate are added to the composition to interact with the polymeric materials. The compositions are particularly sui table for sealing and obturating dental root canals and root apices. The com position provides a stable barrier to bacterial&#39; and fluid leakage in the ro ot canal system of a tooth. In addition, the compositions help promote the g rowth of new bone and tissue surrounding the root-tip area or dentin tissue that covers an injured or amputated pulp.
PURPOSE:The titled film, prepared by adding a specific amount of polypeptide to gelatin, having improved solubility and such improved adhesive property as not to leak the contents therein, e.g. a drug. CONSTITUTION:A soft capsule film prepared by adding 0.5-10wt%, preferably 1.5-6wt%, based on gelatin, polypeptide, having &lt;=10,000, preferably 500-5,000, more preferably 1,000-2,000, molecular weight to the gelatin. The resultant soft capsule film will not deteriorate the solubility thereof even in storing for a long term and is capable of retaining the good adhesive property of the film. Another well-known component, e.g. glycerol, sorbitol, ethylparaben or propylparaben, may be added thereto in addition to the above-mentioned components.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medically useful capsule containing no including gelatin.  &lt;P&gt;SOLUTION: Starch-containing matter is processed into homogenized material in a first processor, and then into thermoplastic material in a second processor to be an extrusion-molded film at the outlet of the second processor. Then, in an intermittent molding method, it is formed into be the capsule. Obtained material has at least 40ml/g in the Staudinger index, so that at least 100% rupture point distortion of extruded material is assured at encapsulation temperature. In particular, a soft capsule including a singular constitution capsule cover can be produced of this material in a rotary die method.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
Systems, methods, and computer-readable media for optimizing a clinical experience are provided. Individuals may be approved by a patient to receive notifications of clinical events. The notifications may be accessed from the patient&#39;s electronic health record. In embodiments, a location of a clinician associated with a patient and a location of the patient are received. A determination whether the clinician is near the patient is made. Upon determining that the clinician is near the patient, a notification is sent to a non-present party (e.g., a family member) via a mobile device. Such notifications include individuals in the clinical process and avoid missed opportunities for interactions with clinicians.
PURPOSE: To obtain a diphenyldisulfide compound having excellent inhibitory action on IL-1β production and on TNFαliberation, low toxicity and effective for preventing and treating septicemia, chronic rheumatoid arthritis, etc. CONSTITUTION: This compound is shown by formula I (R1 is imidazolyl, pyrazolyl, etc., R2 is imidazolinyl, pyrazolinyl, etc.; R3 and R4 are each H, methyl, n-propyl, etc.). The compound is obtained by reacting 1mol of a di(2- aminophenyl)disulfide compound of formula II with 0.5-4mol of a compound of the formula R&#39;Hal (R&#39; is a halide of a 5-membered or 6-membered heterocyclic compound containing two nitrogen atoms as hetero atoms, etc.) to monosubstitute heterocyclic groups for the two amino groups of the compound of formula II. The reaction is preferably carried out in an inert organic solvent such as methanol in the presence of a base such as NaOH at a normal temperature to the boiling temperature of the solvent.
A chimeric protein with an anchor region and anticoagulant activity is described.  Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).  These anticoagulant proteins are prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation. The anchor region can be any entity capable to attaching the protein to the cell lipid bilayer.  These regions can be the transmembrane sequences from membrane proteins such as the HLA class I or CD4 proteins.  Alternatively, the anchor region might be a sequence conferring on the protein the ability to associate extracellularly with a membrane protein without the protein itself being inserted into the cell membrane. The anticoagulant can comprise the sequence of any anticoagulant polypeptide such as heparin, TAPs (tick anticoagulant peptides), antithrombin, hirudins, TFPIs (tissue factor pathway inhibitors) and snake venom factors. The protein further comprises a targeting sequence that prevents the protein from being constitutively expressed at the cell surface.  The targeting sequence is a polypeptide sequence that can target a nascent polypeptide to a secretory granule that does not fuse with the cell&#39;s plasma membrane until the cell is suitably stimulated.  For example, Weibel-Palade bodies do not fuse with the plasma membrane until the endothelial cell surface is stimulated by a secretagogue, such as thrombin or fibrin. Figure 1 shows maps of hirudin-CD4 chimeric proteins and constructs.  (A) HLA-hirudin-CD4 constructs with glycine linkers. (B) HLA-hirudin-CD4 construct with human P-selectin C-terminal, with the specific targeting sequence underlined.
The novel positively charged non-steroidal anti-inflammatory drugs shown in general formulas (1, 2a, 2b, 2c or 2d), namely &#39;structural formulas 1, 2a, 2b, 2c or 2d&#39;, have been designed and synthesized. The compounds represented by the general formulas (1, 2a, 2b, 2c or 2d), namely &#39;structural formulas 1, 2a, 2b, 2c or 2d&#39;, can be prepared through reaction between the metal salts, organic alkali salts or immobilized alkali salts of the non-steroidal anti-inflammatory drugs and appropriate halides. The positively charged amino in a prodrug of the invention greatly improves the solubility of the drugs in water and can further combine with negative charges on the phosphate terminal groups of a biological membrane. Thus, the local concentrations of the drugs on the biological membrane or the outer side of the skin are very high so as to facilitate the diffusion of the prodrugs from high-concentration areas to low-concentration areas. The biological membrane can be slightly disturbed through the combination so as to allow parts of space for the fat soluble parts of the prodrugs. When molecules of the biological membrane move, the biological membrane is slightly squeezed due to the combination effects of the prodrugs, and when the amino is not protonized, the amino in the prodrugs is separated from the phosphate terminal groups of the biological membrane, and the prodrugs completely penetrate into the biological membrane. When the amino in the prodrugs moves to the other side of the biological membrane and therefore the amino is protonized, the prodrugs are drawn into the cytoplasm, a half-liquid-state aqueous solution or a suspension solution. The prodrugs can be used for the treatment and prevention of diabetes mellitus (type I and/or type II), pathoglycemia and dyslipidemia, apoplexia, myocardial infarction and other cardiac and cardiovascular diseases, an Alzheimer&#39;s disease, a Parkinson&#39;s disease and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS) and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD) and other muscle abnormalities, inflamed hemorrhoids, cryptitis and other anorectal inflammatory conditions, pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune hepatitis, autoimmune nephritis, phlebitis and other inflammations, skin cancers, breast cancers, colon-rectal cancers, oral cancers and other cancers, scars, abnormal cutaneous vascular lesions, birthmarks and pigmented naevus (pigment), and the prodrugs can directly perform cutaneous penetration without skin permeation promoters.